{"id":"NCT00116688","sponsor":"Amgen","briefTitle":"Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","officialTitle":"An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-08","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2005-07-01","resultsPosted":"2011-04-06","lastUpdate":"2013-12-18"},"enrollment":313,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Thrombocytopenia","Idiopathic Thrombocytopenic Purpura"],"interventions":[{"type":"BIOLOGICAL","name":"Romiplostim","otherNames":["AMG 531","Nplate"]}],"arms":[{"label":"Romiplostim","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the safety of romiplostim as a long-term treatment in thrombocytopenic subjects with ITP, to evaluate the long-term platelet response to romiplostim, and to evaluate changes in patient reported outcomes due to the use of romiplostim. Participants must have previously completed a romiplostim ITP study.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"Duration of treatment plus 8 weeks (up to 285 weeks)","effectByArm":[{"arm":"Romiplostim in Adults","deltaMin":284,"sd":null},{"arm":"Romiplostim in Pediatric Population","deltaMin":19,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18981291","23432528","19671919"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":117,"n":291},"commonTop":["Headache","Nasopharyngitis","Fatigue","Contusion","Upper respiratory tract infection"]}}